Fortress Biotech Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors

NEXT STORY
Update: Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide License and Co-Development of Its Broad-Spectrum Anti-Cancer Drug, KTH 222
PREV STORY
The World Market for Orphan Drugs (2019-2023): Emergence of Combination Therapies & Novel Targets Spurs Market Growth
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 – A Cancer Cell Specific Anticancer Agent

ROCKVILLE, Md., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a ...

author_avatar
NASDAQ Market News

Shire plc : Notice of Results

Shire to announce second quarter 2018 results Dublin, Ireland - July 23, 2018 - ...

author_avatar
NASDAQ Market News

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus

author_avatar
NASDAQ Market News